A5 Labs Expands Management for the Development of Interferon Projects
Published: Nov 02, 2010
MONTREAL, QUEBEC--(Marketwire - November 02, 2010) - A5 Laboratories Inc. (A5 Labs) (OTCBB: AFLB) today announced the appointment of Dr. Abderrazzak Merzouki to the position of Director of Cell Engineering and Biotherapeutics. Dr. Merzouki is molecular biologist and immunologist with extensive experience in the advancement of biological molecules, such as interferons, through their preclinical and clinical phases of analysis and development. He has previously been a consultant in the development of products for Introgen Therapeutics Inc., Gencell (Japan), Aventis Pharma, Genomics One, ID Biomedical, Shire and Rhone Poulenc Rorer. In his role at A5 Labs, Dr. Merzouki will direct all aspects of interferon product development as well as strengthening and enhancement of the company's patent portfolio.
Dr. Merzouki obtained his M.Sc. and Ph.D. in immunology from Armand-Frappier Institute in Quebec in 1996 and received his post-doctoral training at the University of British Columbia and BC Center for Excellence in HIV/AIDS research. From 1999 until 2007 he was professor of Immunology at the Armand-Frappier institute. In 2007, Dr. Merzouki joined the Institute of Biomedical Engineering at the Ecole Polytechnique de Montreal as a senior scientist where he has directly been involved in the latest research and development of interferon based therapies. Dr. Merzouki has over 25 publications in the most respected journals in the field of cellular and molecular biology.
"I am very pleased to welcome Dr. Merzouki to our interferon development team. His extensive knowledge of the latest developments in interferon therapies will provide a significant depth to our management and will put A5 Labs at the forefront of interferon product development," said Dr. Richard Azani, President and CEO.
About A5 Labs:
A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.
Safe Harbor Statement:
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to A5, its management, or its ability to develop interferon products or strengthen its intellectual property, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5's products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5's expansion efforts, economic conditions in the industry and the financial strength of A5's customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.